-
71.发明公开公开(公告)号：US20230347316A1
公开(公告)日：2023-11-02
申请号：US17981262
申请日：2022-11-04
Applicant: Cytiva Bioprocess R&D AB
Inventor： Martin HALL , Sture LARSSON , Andreas MURANYI , Gustav RODRIGO , Jinyu ZOU , Per-Mikael ABERG
IPC: B01J20/24 , B01D15/38 , B01J20/286 , C07K1/22 , B01J20/32 , C07K14/31 , C07K16/00 , C07K17/00 , B01J20/28 , B01J20/285 , B01J20/289 , C07K17/10
CPC classification number: B01J20/24 , B01D15/3809 , B01J20/286 , C07K1/22 , B01J20/3274 , C07K14/31 , C07K16/00 , C07K17/00 , B01J20/28019 , B01J20/285 , B01J20/289 , B01J20/3212 , B01J20/3219 , B01J20/3293 , C07K17/10 , C07K2317/55 , B01J2220/52 , B01J2220/54
Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
-
公开(公告)号：US11753438B2
公开(公告)日：2023-09-12
申请号：US16095753
申请日：2017-05-10
Applicant: CYTIVA BIOPROCESS R&D AB
Inventor： Annika Forss , Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
IPC: C07K1/22 , B01J20/26 , B01J20/285 , B01J20/286 , B01J20/32 , C07K14/31 , C07K16/00 , C07K16/12 , C07K17/10
CPC classification number: C07K1/22 , B01J20/267 , B01J20/285 , B01J20/286 , B01J20/3274 , C07K14/31 , C07K16/00 , C07K16/1271 , C07K17/10 , B01J2220/52
Abstract: The present invention concerns a method of cleaning and/or sanitizing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support. The method comprises the steps of: a) optionally purifying a mixture comprising a first immunoglobulin using the separation matrix; b) providing a cleaning liquid comprising at least 50% by volume of an aqueous alkali metal hydroxide solution; and c) cleaning and/or sanitizing the separation matrix by contacting the cleaning liquid with the separation matrix for a predetermined contact time. The alkali-stabilized Protein A domains comprise mutants of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO 51 or SEQ ID NO 52, wherein the amino acid residues at positions 13 and 44 of SEQ ID NO 51 or 52 are asparagines and wherein at least the asparagine residue at position 3 of SEQ ID NO 51 or 52 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
-
公开(公告)号：US20230279047A1
公开(公告)日：2023-09-07
申请号：US18298857
申请日：2023-04-11
Applicant: Cytiva BioProcess R&D AB
Inventor： Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
IPC: C07K1/22 , B01D15/38 , B01J20/24 , B01J20/28 , B01J20/286 , B01J20/32 , C07K14/31 , C07K16/00 , C07K16/06 , C07K17/10
CPC classification number: C07K1/22 , B01D15/3809 , B01J20/24 , B01J20/28016 , B01J20/28078 , B01J20/286 , B01J20/3212 , B01J20/3274 , C07K14/31 , C07K16/00 , C07K16/065 , C07K17/10
Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein:
a) the ligands comprise multimers of alkali-stabilized Protein A domains, and
b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.-
公开(公告)号：US20230091082A1
公开(公告)日：2023-03-23
申请号：US18059929
申请日：2022-11-29
Applicant: Cytiva BioProcess R&D AB
Inventor： Martin Hall , Karolina Busson , Jean-Luc Maloisel , Helena Skoglar
IPC: C07K1/18 , B01J41/20 , B01D15/36 , B01D15/38 , A61K38/36 , A61K38/48 , A61K35/16 , C12N9/64 , B01D15/34 , C07K14/47 , C07K14/755 , C07K14/765 , C07K16/00
Abstract: The present invention relates to the field of chromatography. More closely, the invention relates to a chromatographic method for purification of proteins, such as Factor VIII, von Willebrand factor and Factor IX. The chromatographic method is performed on a matrix comprising an inner porous core and outer porous lid surrounding said core.
-
公开(公告)号：US11566082B2
公开(公告)日：2023-01-31
申请号：US15525688
申请日：2015-11-11
Applicant: Cytiva BioProcess R&D AB
Inventor： Gustav Rodrigo , Tomas Bjorkman , Mats Ander
Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO 26 or SEQ ID NO 27, wherein at least the alanine residue at the position corresponding to position 42 in SEQ ID NO:4-7 has been mutated to arginine and/or wherein at least the aspartic acid residue at the position corresponding to position 37 in SEQ ID NO:4-7 has been mutated to glutamic acid.
-
Patent Agency Ranking
76.发明授权公开(公告)号：US11517879B2
公开(公告)日：2022-12-06
申请号：US17107600
申请日：2020-11-30
Applicant: Cytiva Bioprocess R&D AB
Inventor： Martin Hall , Sture Larsson , Andreas Muranyi , Gustav Rodrigo , Jinyu Zou , Per-Mikael Aberg
IPC: B01J20/24 , B01D15/38 , B01J20/286 , C07K1/22 , B01J20/32 , C07K14/31 , C07K16/00 , C07K17/00 , B01J20/28 , B01J20/285 , B01J20/289 , C07K17/10
Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
-
公开(公告)号：US20220266170A1
公开(公告)日：2022-08-25
申请号：US17741394
申请日：2022-05-10
Applicant: Cytiva BioProcess R&D AB
Inventor： Jan Bergstrom , Gunnar Glad , Bo-Lennart Johansson , Jean-Luc Maloisel , Nils Norrman , Tobias E. Soderman
IPC: B01D15/32 , B01J20/285 , B01J20/287 , B01J39/26 , B01J20/28 , B01J20/32 , C07K1/20 , C07K16/00 , C12N7/00 , G01N1/40
Abstract: The present invention is within the field of chromatography. More precisely, it relates to a novel chromatography medium, namely a hydrophobic medium provided with different lids excluding molecules over a certain size due to the porosity of the hydrophobic medium and/or the porosity of the lid. The invention also relates to use of the separation medium for purification of large molecules, which do not enter the separation medium, as well as small molecules, which enter the separation medium and are eluted from there.
-
公开(公告)号：US20220204555A1
公开(公告)日：2022-06-30
申请号：US17607747
申请日：2020-05-11
Applicant: CYTIVA BIOPROCESS R&D AB
Inventor： Martin HALL , Mats ANDER , Mikael BERG , Sandeep KRISTIANSSON
IPC: C07K1/22 , C07K14/755
Abstract: The present invention relates to a method for purification of plasma proteins. More closely, the invention relates to a method using magnetic beads for separation of different plasma proteins from a plasma fraction, such as a cryoprecipitate or cryosupernatant of plasma, or alternatively directly from cell culture of recombinant plasma proteins.
-
公开(公告)号：US20220106462A1
公开(公告)日：2022-04-07
申请号：US17550830
申请日：2021-12-14
Applicant: Cytiva BioProcess R&D AB
Inventor： Per Erik Emilsson , Susanna Klara Margareta Lindberg , Jonny Wernersson , Jonas Gustafsson , Adam Hurynowicz
Abstract: The invention discloses a method of manufacturing polysaccharide beads, comprising the steps of: i) providing a water phase comprising an aqueous solution of a polysaccharide; ii) providing an oil phase comprising at least one water-immiscible organic solvent and at least one oil-soluble emulsifier; iii) emulsifying the water phase in the oil phase to form a water-in-oil (w/o) emulsion; and iv) inducing solidification of the water phase in the w/o emulsion, wherein the organic solvent is an aliphatic or alicyclic ketone or ether.
-
公开(公告)号：US11285460B2
公开(公告)日：2022-03-29
申请号：US15120845
申请日：2015-02-18
Applicant: Cytiva BioProcess R&D AB
Inventor： Jean-Luc Maloisel , Karolina Busson , Karol Lacki , Bjorn Noren , Helena Skoglar
IPC: B01D15/12 , B01D15/20 , B01D15/30 , B01D15/36 , B01J20/28 , B01J20/286 , B01J20/32 , C07K1/22 , C07K14/765 , C07K14/77 , C12N1/20
Abstract: The invention discloses a separation matrix for purification of biological particles, comprising a plurality of particles having a porous core entity and a porous shell entity covering the core entity, wherein the core entity comprises at least 50 micromole/ml primary amines present on covalently attached ligands displaying at least two primary amines per ligand and the shell entity comprises less than 20 micromole/ml primary amines The invention further discloses a method of purifying biological particles and a method of manufacturing a separation matrix.
-
-
-
-
-
-
-
-
-
Search Results
88
records
(took 0.023 seconds)
